-

Thermo Fisher Scientific’s Clinical Research Business Recognized by ISG for Digital Services Leadership

The PPD clinical research business has been named a leader in digital solutions and services by ISG for four consecutive years

WILMINGTON, N.C.--(BUSINESS WIRE)--The PPD clinical research business of Thermo Fisher Scientific, the world leader in serving science, has been honored for industry leadership in digital services by Information Services Group (ISG), a leading global technology research and advisory firm. The business was recognized as an ISG Provider Lens Leader for its digital transformation services in clinical development and patient engagement, as well as pharmacovigilance and regulatory affairs.

ISG’s honor focuses on the business’ ability to provide access to patients to clinical trials of promising new medical therapies in a more efficient and effective way. It also recognizes the ability to help pharmaceutical and biotech customers accelerate the delivery of safe and effective medicines to the marketplace while addressing issues of patient diversity, health equity and sustainability in clinical research.

In the 2024 ISG Provider Lens™ Life Sciences Digital Services Global Report, ISG specifically recognized Thermo Fisher’s clinical research business for its decentralized trials capabilities, full-spectrum expertise across various therapeutic areas and customized, diverse patient engagement solutions. ISG highlighted the strength of the business’ robust patient recruitment and retention strategies that continue to overcome common barriers in clinical trials, such as lack of awareness, access, trust, inconvenience and socioeconomic challenges.

Additionally, the report highlighted the business’ advanced disease simulation and modeling, along with its comprehensive pharmacovigilance and regulatory solutions, which includes artificial intelligence integration and machine learning. The PPD clinical research business leverages a diverse range of technology solutions to propel advancements in areas such as case processing, safety profiling, regulatory intelligence collection and compilation.

“We are honored to once again receive this recognition from ISG, affirming our steadfast market presence and exceptional industry leadership,” said Brittany Erana, vice president and general manager, Patient First Digital Solutions, clinical research, Thermo Fisher Scientific. “We are dedicated to revolutionizing patient-centered clinical research by harnessing cutting-edge patient and site-enabling technology, while adopting a comprehensive approach that prioritizes enhancing the patience experience. This unwavering commitment to patients empowers us and our customers to introduce life-changing medicines to the global market.”

In 2023, Thermo Fisher invested $1.3 billion in research and development to deliver new technologies across all businesses, including the PPD clinical research business. For its ISG Provider Lens report, ISG conducted an independent review of life science companies offering digital services, then selected the top 20 companies for a deep analysis and placement on its Provider Lens Quadrant. ISG’s findings cover defined technology and service categories, as well as industry-specific capabilities.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact Information:
Nadine Maeser
nadine.maeser@ppd.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Summary
The PPD clinical research business of Thermo Fisher Scientific has been recognized as an ISG Provider Lens Leader for its digital services.
Release Versions

Contacts

Media Contact Information:
Nadine Maeser
nadine.maeser@ppd.com

More News From Thermo Fisher

Thermo Fisher Scientific Opens U.S. Flagship Bioprocess Design Center to Accelerate the Delivery of Life-changing Therapies

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the opening of its flagship U.S. Bioprocess Design Center (BDC) at the company’s Plainville, Mass., site, expanding the facility to support customers in developing and scaling biologics. The new center brings together advanced bioproduction capabilities and hands-on collaboration to help customers accelerate process development and bring transformative therapies to patients faste...

Thermo Fisher Scientific to Host Investor Day

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, will hold its 2026 Investor Day on Wednesday, May 20, 2026, starting at 9:00 a.m. ET in New York City. The format will feature presentations by members of Thermo Fisher Scientific’s senior management team and conclude with a Q&A session. The live webcast of the presentation can be accessed via the Investors section of our website, https://ir.thermofisher.com. A replay of the webc...

Thermo Fisher Scientific Signs Agreement to Sell its Microbiology Business to Astorg

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has signed a definitive agreement to sell its microbiology business to Astorg, a leading pan-European private equity firm, for consideration of approximately $1.075 billion, consisting of cash and a $50 million seller note. The microbiology business provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food...
Back to Newsroom